We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Cephalon (MM) | NASDAQ:CEPH | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 81.49 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
The U.S. Justice Department has asked Cephalon Inc. (CEPH) about documents relating to alleged off-label promotion of its Treanda treatment for chronic lymphocytic leukemia, the pharmaceutical industry news site Pharmalot.com reported Monday.
The June request to the Pennsylvania-based drug maker concerned first-line treatment of non-Hodgkin's lymphoma, for which Treanda isn't approved, according to sources familiar with the request. Also requested were clinical studies that could be used to support off-label use before the studies were completed or submitted for review by the U.S. Food and Drug Administration.
A Cephalon spokeswoman declined to comment, Pharmalot.com reported.
Israeli drug maker Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) is attempting to complete a $6.2 billion acquisition of Cephalon, and has said it expects the deal to be completed during the third quarter, pending approval by U.S. and European regulators as well as Cephalon shareholders.
Full story at http://www.pharmalot.com/2011/07/feds-probe-cephalon-for-off-label-treanda-promotion/
-Dow Jones Newswires; 212-416-2900
1 Year Cephalon Chart |
1 Month Cephalon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
